SCHEMBL19554429

SCHEMBL19554429

OCc1nnc(-c2cccc(I)c2)o1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 4/20 0.65
▸ APP P05067 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.44
▸ LMNA P02545 2/20 0.44
▸ RAB9A P51151 7/20 0.42
▸ SMN1; SMN2 Q16637 6/20 0.42
▸ NPC1 O15118 6/20 0.42
▸ TSHR P16473 5/20 0.42
▸ HPGD P15428 3/20 0.42
▸ GPR55 Q9Y2T6 1/20 0.42
▸ CCNB2 O95067 1/20 0.40
▸ CDK1 P06493 1/20 0.40
▸ CCNB1 P14635 1/20 0.40
▸ GSK3A P49840 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ CCNB3 Q8WWL7 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ TP53 P04637 4/20 0.39
▸ MECP2 P51608 1/20 0.39
▸ NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2288774 0.84 APP (0.51) NOTUMAPPALDH1A1LMNARAB9A
SCHEMBL30566766 0.84 ALDH1A1 (0.65) NOTUMAPPALDH1A1LMNARAB9A
SCHEMBL19553547 0.84 ALDH1A1 (0.65) NOTUMAPPALDH1A1LMNARAB9A
SCHEMBL10299062 0.83 APP (0.50) NOTUMAPPALDH1A1RAB9ASMN1; SMN2
SCHEMBL2284800 0.80 POLB (0.48) NOTUMAPPALDH1A1LMNARAB9A
SCHEMBL31049648 0.80 NOTUM (0.68) NOTUMAPPALDH1A1LMNARAB9A
SCHEMBL28582160 0.79 NOTUM (1.00) NOTUMALDH1A1LMNARAB9ASMN1; SMN2
SCHEMBL22360380 0.75 POLB (0.39) NOTUMAPPALDH1A1LMNARAB9A
SCHEMBL753110 0.75 APP (0.55) NOTUMAPPALDH1A1RAB9ASMN1; SMN2
SCHEMBL6033847 0.74 RAB9A (0.71) NOTUMALDH1A1LMNARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109526220-B Tetrahydropyrimidine and tetrahydropyridino-diazepine compounds for use in the treatment of pain and pain related conditions 埃斯特维制药股份公司 2021-12-21 — — CN disclosed
US-10590140-B2 Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions ESTEVE PHARMACEUTICALS, S.A. (ES) 2020-03-17 — — US disclosed
EP-3452475-B1 TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS ESTEVE PHARMACEUTICALS SA (ES) 2020-02-26 — — EP disclosed
US-20190144455-A1 TETRAHYDROPYRIMIDODIAZEPINE AND DIHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-05-16 — — US disclosed
EP-3452475-A1 TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-03-13 — — EP disclosed
WO-2017191304-A1 TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2017-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144455-A1 TETRAHYDROPYRIMIDODIAZEPINE AND DIHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS CACNA1G, CACNA1B, CACNA1D NOTUM 3816/4885APP 905/4885ALDH1A1 1302/4885
US-10590140-B2 Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions CACNA1G, CACNA1B, CACNA1D NOTUM 3816/4885APP 905/4885ALDH1A1 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback